NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS

诺龙在艾滋病毒相关减肥中的作用

• 批准号: 6305594
• 负责人: Kathleen Mulligan
• 金额: $ 0.06万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305594
• 关键词: AIDS; HIV infections; androgen analog; body composition; body weight; cachexia; clinical research; clinical trials; drug screening /evaluation; functional ability; hormone therapy; human subject; human therapy evaluation; immunity; injection /infusion; intramuscular injections; medical complication; nutrient intake activity; nutrition related tag; outcomes research; pathologic process; quality of life; weight loss

This is a randomized, double-blind, placebo-controlled study in patients with HIV-associated weight loss. Eligible individuals will receive nandrolone decanoate or placebo by weekly intramuscular injection for 12 weeks. All patients who successfully complete a 12-week placebo-controlled phase will be eligible to receive open-label nandrolone for an additional 12 weeks. Response to treatment will be evaluated by measuring body weight and composition, functional performance, quality of life, and energy and macronutrient intake. Safety, HIV disease progression, and immunologic status will be closely monitored throughout the study.

这是一项随机、双盲、安慰剂对照研究，在HIV相关体重减轻的患者中进行。 合格的个体将接受癸酸诺龙或安慰剂，每周肌肉注射12周。 所有成功完成12周安慰剂对照期的患者将有资格接受额外12周的开放标签诺龙。 将通过测量体重和组成、功能表现、生活质量以及能量和大量营养素摄入来评价对治疗的反应。 整个研究期间将密切监测安全性、HIV疾病进展和免疫状态。